聚乙二醇干扰素α-2a联合利巴韦林、双环醇治疗慢性丙肝的临床疗效评价-现代医学

聚乙二醇干扰素α-2a联合利巴韦林、双环醇治疗慢性丙肝的临床疗效评价

单位：1. 南京市第二医院肝病科, 江苏南京 210003;
2. 江苏大学医学院临床医学院, 江苏镇江 212000

分类号：R512.6

出版年·卷·期（页码）：2017·36·第五期（641-644）

摘要：

目的：探讨聚乙二醇干扰素α-2a联合利巴韦林及双环醇治疗慢性丙型肝炎（慢性丙肝）的临床效果。方法：按照数字随机分组法将50例基因1型慢性丙肝患者随机分为实验组和对照组，实验组给予聚乙二醇干扰素α-2a联合利巴韦林、双环醇治疗，对照组给予聚乙二醇干扰素α-2a联合利巴韦林治疗，比较两组治疗期间肝功能改善状况、丙型肝炎病毒应答率以及不良反应发生情况。结果：治疗后第4、12、24周肝功能[总胆红素（TBIL）、谷丙转氨酶（ALT）、谷草转氨酶（AST）]复常率实验组均明显优于对照组，差异均有统计学意义（P < 0.05）。两组HCV RNA应答率比较，快速病毒学应答（RVR）、早期病毒学应答（EVR）、完全早期病毒学应答（eEVR）、持续病毒应答率（SVR）实验组明显优于对照组36%vs.8%、80%vs.52%、68%vs.40%，差异均有统计学意义（P < 0.05）。治疗期间两组不良反应发生情况比较，差异无统计学意义（P > 0.05）。结论：在聚乙二醇干扰素α-2a联合利巴韦林治疗基础上加用双环醇治疗慢性丙肝，可明显改善患者肝功能、提高丙型肝炎病毒应答率。

Objective: To explore the curative effects of peg-interferon α-2a plus ribavirin and bicyclol in patients with chronic hepatitis C(HCV). Methods: Fifty patients with HCV were randomly divided into experimental group and control group.The experiment group was treated by peg-interferon α-2a plus ribavirin and bicyclol, and the control group was treated by peg-interferon α-2a plus ribavirin.The improvement of liver function,the response rates in the patients with HCV and side effects during therapy were compared between the two groups.Results: Liver function recovery rate at 4,12 and 24 weeks after the treatment were significantly better in the experimental group than those in the control group(P<0.05).The response rates such as RVR,EVR,eEVR and SVR were higher in the experimental group than those in the control group(36%vs.8%,80%vs.52%,68%vs.40%,P<0.05).There were no statistically significant differences in the side effects between the two groups. Conclusion: Peg-interferon α-2a plus ribavirin and bicyclol can improve the liver function and increase the response rates to HCV RNA in patients with chronic hepatitis C.

参考文献：

[1] 中华医学会传染病与寄生虫学分会,肝病学分会.丙型肝炎防治指南[J].中华肝脏病杂志,2004,12:194-198.
[2] 张泽敏,于兰芳,李一鸣,等.聚乙二醇干扰素α-2a联合利巴韦林联合熊去氧胆酸治疗慢性丙型肝炎的临床疗效评价[J].世界华人消化杂志,2014,22(7):1005-1009.
[3] 徐庆年,杨宗国,陆云飞,等.聚乙二醇干扰素联合利巴韦林治疗经治慢性丙型肝炎患者的回顾性分析[J].世界华人消化杂志,2013,21(19):1797-1802.
[4] 李永春,陈焰.聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎45例的疗效评价[J].临床医学工程,2013,20(8):951-952.
[5] 刘耕陶.双环醇的抗病毒与肝细胞保护作用及其作用机制[J].中国新药杂志,2001,10(5):325-327.
[6] 赵冬梅,刘耕陶.双环醇对刀豆蛋白A所致小鼠肝细胞核DNA损伤的保护作用[J].中华医学杂志,2001,81(14):844-848.
[7] 余祖江,江河清,阚全程,等.双环醇抗病毒与保护肝细胞作用的动态观察和分析[J].药物研究,2003,12(8):27.
[8] LI M,LIU G T. Inhibition of Fas/FasL mRNA expression and TNF-alpha release in concanavalin A-induced liver injury in mice by bicyclol[J].World J Gastroenterol,2004,10(12):1775-1779.
[9] 姚光弼,计焱焱,周霞秋,等.双环醇治疗慢性丙型肝炎的临床研究[J].中华医学杂志,2002,82(14):958-960.
[10] 徐标,韩春荣.双环醇抗肝炎病毒及肝损伤保护作用的研究进展[J].华中医学杂志,2005,29(3):222.
[11] 赖春颜,伍美琳,廖珊.双环醇治疗慢性丙型病毒性肝炎的疗效观察[J].中国热带医学,2009,9(7):1241-1242.
[12] 郭强,张玉江,王靖,等.双环醇治疗慢性丙型肝炎的临床应用评价[J].中国医院用药评价与分析,2003,3(6):337-339.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录